ATHEROGENIC NORMOLIPIDEMIA IN MEN WITH CORONARY ATHEROSCLEROSIS: SOME PECULIARITIES OF SUBFRACTIONAL DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS
https://doi.org/10.15372/ATER20180301
Abstract
Background: Plasma apo B-containing lipoproteins of low densities represent a heterogeneous population of particles varying by physicochemical composition, functional activity, and atherogenicity. Aim: To study some peculiarities in low density lipoproteins subfractional distribution in men with coronary atherosclerosis at normolipidemia. Material and methods: Patients with angiographically documented coronary atherosclerosis were included into the study ( n = 177; mean age 62.5 ± 9.3 yrs). Lipoprotein subfractional distribution was analyzed using Lipoprint LDL System (Quantimetrix, USA). Results: Out the total cohort normolipidemic patients (total C < 5,0 mmol/l, TG < 1.7 mmol/l, LDL-C < 2.5 mmol/l) with coronary atherosclerosis were selected and thereafter were split into those without small dense LDL (sdLDL) - group 1, n = 16, and and group 2 with presence of sdLDL ( n = 22). Patients from group 2 had lower portion of IDLB: 7.0 ± 1.2 vs 8.5 ± 1.0 %, IDLА: 7.9 ± 1.7 vs 9.6 ± 2.5 %, and higher LDL2 portion: 7.0 ± 2.0 vs 4.3 ± 1.6 %. In group 2 C level in LDL2 was higher than in group 1 while in IDL B it appeared to be lower. Mean LDL particles size in group 2 was lower as well: 270.7 ± 1.3 и 273.8 ± 0.8 Е. Conclusion. In men with coronary atherosclerosis at normolipidemia two different patterns of subfractional distribution of apo B-containing lipoproteins were detected. Presence of sd LDL associated with decreased LDL size could be regarded as more atherogenic profile even at normal lipid levels.
About the Authors
I. N. Ozerova
National Medical Research Center for Preventive Medicine of Minzdrav of Russia
Russian Federation
Russian Federation
V. A. Metelskaya
National Medical Research Center for Preventive Medicine of Minzdrav of Russia
Russian Federation
Russian Federation
N. E. Gavrilova
National Medical Research Center for Preventive Medicine of Minzdrav of Russia
Russian Federation
Russian Federation
References
1. Hirayama S., Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease // Clin. Chim. Acta. 2012. Vol. 24, N 414. P. 215-224. DOI:10.1016/j.cca.2012.09.010.
2. Mora S., Caulfield M.P., Wohlgemuth J. et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial // Circulation. 2015. Vol. 132, N 23. P. 2220-2229. DOI: 10.1161/CIRCULATIONAHA.115.016857.
3. Lawler P.R., Akinkuolie A.O., Chu A.Y. et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol // J. Am. Heart Assoc. 2017. Vol. 6, N 7. P. e005549. DOI: 10.1161/JAHA.117.005549.
4. Dallmeier D., Koening W. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA?) and lipoprotein(a) (Lp(a) // Best. Pract. Res. Clin. Endocrnol. Metab. 2014. Vol. 28, N 3. P. 281-294. DOI: 10.1016/j.beem.2014.01.003.
5. Sniderman A.D., Williams K., Contois J.H. et al. A meta-analysis of low-demsity lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk // Circ. Cardiovasc. Outcomes. 2011. N 4. P. 337-345.
6. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity // J. Lipid Res. 2002. Vol. 43, N 9. P. 1363-1379. DOI: 10.1194/jlr. R200004-JLR200September 2002.
7. Hoefner D.M., Hodel S.D., O’Brein J.F. et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System // Clin. Chem. 2001. Vol. 47, N 2. P. 266-274.
8. Carmena R., Duriez P., Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis // Circulation. 2004. Vol.109. P. III-2-III-7. DOI: org/10.1161/01.CIR.0000131511.50734.44.
9. Diffenderfer M.R., Schaefer E.J. The composition and metabolism of large and small LDL // Curr. Opin. Lipidol. 2014. Vol. 25, N 3. P. 221-226. DOI: 10.1097/MOL.0000000000000067.
10. Srisawasdi P., Vanavanan S., Rochanawutanon M. et al. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations // Clin. Biochem. 2013. Vol. 46, N 15. P. 1509-1515. DOI:10.1016/j.clinbiochem.2013.06.021.
11. Varbo A., Benn M., Nordestgaard B.G. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment // Pharmacol. Ther. 2014. Vol. 141, N 3. P. 358-367. DOI: 10.1016/j.pharmthera.2013.11.008.
12. El Harchaoui K., van der Steeg W.A., Stroes E.S. et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study // J. Am. Coll. Cardiol. 2007. Vol. 49, N 5. P. 547-553. DOI: 10.1016/j.jacc. 2006.09.043.
13. Рагино Ю.И. Мелкие плотные субфракции липопротеинов низкой плотности и атерогенез // Рос. кардиол. журн. 2004. № 4. С. 84-90.
14. Озерова И.Н., Перова Н.В., Метельская В.А. и др. Субфракционный спектр липопротеинов низких плотностей при разной степени стенозов коронарных артерий // Кардиоваскулярная терапия и профилактика. 2013. № 4. С. 16-20.
15. Уткина Е.А., Афанасьева О.И., Ежов М.В. и др. Связь различных подфракций липопротеидов с коронарным атеросклерозом у мужчин среднего возраста, получавших терапию статинами // Кардиол. вестн. 2014. Т. 9, № 1. С. 68-76.
16. Oravec S., Dukat A., Gavornik P. et al. Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. is there a need to change our approach to diagnosing dyslipidemia? // Curr. Med. Chem. 2014. Vol. 21, N 25. P. 2892-2901. DOI: 10.2174/0929867321666140303153048.
17. Superko H.R. Advanced lipoprotein testing and subfractionation are clinically useful // Circulation. 2009. Vol. 119, N 17. P. 2383-2395. DOI: 10.1161/CIRCULATIONAHA.108.809582.
18. Davidson M.H. Apolipoprotein measurements: is more widespread use clinically indicated? // Clin. Cardiol. 2009. Vol.32, N 9. P. 482-486. DOI:10.1002/clc.20559.
19. Kucera M., Oravec S., Hirnerova E. et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study // Angiology. 2014. Vol. 65, N 9. P. 794-799. DOI: 10.1177/0003319713507476.
20. Афанасьева О.И., Уткина Е.А., Вихрова Е.Б. и др. Наличие мелких плотных липопротеидов низкой плотности в сыворотке крови человека вызывает накопление холестерина моноцитоподобными клетками линии ТНР-1 // Атеросклероз и дислипидемии. 2018. Т. 30, № 1. С. 38-46.
Review
For citations:
Ozerova I.N., Metelskaya V.A., Gavrilova N.E. ATHEROGENIC NORMOLIPIDEMIA IN MEN WITH CORONARY ATHEROSCLEROSIS: SOME PECULIARITIES OF SUBFRACTIONAL DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS. Ateroscleroz. 2018;14(3):5-11. (In Russ.) https://doi.org/10.15372/ATER20180301
Views:
262
Email this article 